Invex Therapeutics Ltd (ASX:IXC)
Australia · Delayed Price · Currency is AUD 0.1300
0.00 (0.00%)
Jun 17, 2026, 3:46 PM AEST
Invex Therapeutics Market Cap
Invex Therapeutics has a market cap or net worth of 9.77 million as of June 18, 2026. Its market cap has increased by 80.56% in one year.
Market Cap
9.77M
Enterprise Value
5.17M
Revenue
229.08K
Ranking
n/a
PE Ratio
n/a
Stock Price
0.13
Market Cap Chart
Since July 5, 2019, Invex Therapeutics's market cap has decreased from 59.13M to 9.77M, a decrease of -83.48%. That is a compound annual growth rate of -22.80%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 17, 2026 | 9.77M | 8.33% |
| Dec 30, 2025 | 9.02M | 81.82% |
| Dec 23, 2024 | 4.96M | -18.52% |
| Dec 27, 2023 | 6.09M | -85.14% |
| Dec 28, 2022 | 40.96M | -22.70% |
| Dec 31, 2021 | 52.98M | -1.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jul 5, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Proteomics International Laboratories | 19.00M |
| Argenica Therapeutics | 14.13M |
| Cambium Bio | 12.98M |
| Immuron | 9.80M |
| Vectus Biosystems | 9.22M |
| AdAlta | 7.97M |
| Acrux | 7.70M |
| Biotron | 6.75M |